

OFFICE OF THE SECRETARY OF STATE

LAVONNE GRIFFIN-VALADE  
SECRETARY OF STATE

CHERYL MYERS  
DEPUTY SECRETARY OF STATE  
AND TRIBAL LIAISON



ARCHIVES DIVISION

STEPHANIE CLARK  
DIRECTOR

800 SUMMER STREET NE  
SALEM, OR 97310  
503-373-0701

PERMANENT ADMINISTRATIVE ORDER

BP 55-2024

CHAPTER 855

BOARD OF PHARMACY

FILED

06/18/2024 8:49 AM  
ARCHIVES DIVISION  
SECRETARY OF STATE  
& LEGISLATIVE COUNSEL

FILING CAPTION: Amends rule to limit labeling exemption to nasal sprays consistent with 2023 SB 450

EFFECTIVE DATE: 06/20/2024

AGENCY APPROVED DATE: 06/13/2024

CONTACT: Rachel Melvin

971-673-0001

pharmacy.rulemaking@bop.oregon.gov

800 NE Oregon St., Suite 150

Portland, OR 97232

Filed By:

Rachel Melvin

Rules Coordinator

AMEND: 855-115-0350

NOTICE FILED DATE: 04/17/2024

RULE SUMMARY: Amends existing rule by adding that the labeling exemption only applies to nasal sprays as stated in 2023 SB 450.

CHANGES TO RULE:

855-115-0350

Services: Prescribing Practices - Short-acting Opioid Antagonists

(1) A Pharmacist may prescribe any FDA approved short-acting opioid antagonist (e.g., naloxone, nalmeffene) and the necessary medical supplies to administer a short-acting opioid antagonist for opiate overdose.¶¶

(a) When dispensing any opiate or opioid prescription in excess of 50 morphine milligram equivalents (MME); ¶¶

(b) To an individual seeking a short-acting opioid antagonist; ¶¶

(c) To an entity seeking a short-acting opioid antagonist.¶¶

(2) A Pharmacist is not required to label the prescription according to OAR 855-041-1130 if dispensing a FDA approved short-acting opioid antagonist in the form of a nasal spray.¶¶

(3) The Pharmacist must document the encounter, the prescription and maintain records according to OAR 855-104-0055.

Statutory/Other Authority: ORS 689.205

Statutes/Other Implemented: ORS 689.305, ORS 689.681, ORS 689.682, ORS 689.684, ~~2023 HB 2395, 2023 SB 450~~